Pharmacokinetics of Ceftazidime in Koi (Cyprinus carpio) After Single Dose Intramuscular or Intracoelomic Administration
IAAAM 2009
Pamela D. Govett1,2,3; Jennifer Buur1; Avery Krein1; Terry McDowell4; E. Scott Weber, III4
1Western University, College of Veterinary Medicine, Pomona, CA, USA; 2Environmental Medicine Consortium, North Carolina State University, College of Veterinary Medicine, Raleigh, NC, USA; 3California Science Center, Los Angeles, CA, USA; 4University of California, Davis, College of Veterinary Medicine, Davis, CA, USA

Abstract

Ceftazidime pharmacokinetics were studied in adult koi (Cyprinus carpio) following single intramuscular (i.m.) and intracoelomic (i.ce.) injections. Twenty-two koi were divided into two groups. Eleven animals received 20 mg/kg ceftazidime i.m. and eleven received the same dose i.ce. Plasma ceftazidime concentrations were analyzed at predetermined intervals by reverse-phase high performance liquid chromatography. In the preliminary study, the Cmax was 41 µg/ml and the peak was seen at 12 hours post-i.m.-injection. The i.ce. administration demonstrated pharmacokinetics consistent with flip-flop kinetics and reached substantially lower peak plasma concentrations than the i.m. injection around 7 µg/ml. The i.m. concentration was above the minimum inhibitory concentration (MIC) values for Aeromonas hydrophilia and Renibacterium salmoninarum indicating that 20 mg/kg i.m. produces serum ceftazidime concentrations that are within a therapeutic range for koi.

Speaker Information
(click the speaker's name to view other papers and abstracts submitted by this speaker)

Pamela D. Govett
Western University
College of Veterinary Medicine
Pomona, CA, USA


Friendly Reminder to Our Colleagues: Use of VIN content is limited to personal reference by VIN members. No portion of any VIN content may be copied or distributed without the expressed written permission of VIN.

Clinicians are reminded that you are ultimately responsible for the care of your patients. Any content that concerns treatment of your cases should be deemed recommendations by colleagues for you to consider in your case management decisions. Dosages should be confirmed prior to dispensing medications unfamiliar to you. To better understand the origins and logic behind these policies, and to discuss them with your colleagues, click here.

Images posted by VIN community members and displayed via VIN should not be considered of diagnostic quality and the ultimate interpretation of the images lies with the attending clinician. Suggestions, discussions and interpretation related to posted images are only that -- suggestions and recommendations which may be based upon less than diagnostic quality information.

CONTACT US

777 W. Covell Blvd., Davis, CA 95616

vingram@vin.com

PHONE

  • Toll Free: 800-700-4636
  • From UK: 01-45-222-6154
  • From anywhere: (1)-530-756-4881
  • From Australia: 02-6145-2357
SAID=27